(Yicai Global) Sept. 27 -- Shares of Frontier Biotechnologies rose after the Chinese medical company said its inhaled therapy to treat Covid-19 symptoms can begin clinical trials.
Frontier Biotechnologies has reported positive data from the Phase I clinical trial of its drug candidate, FB2001 (Bofutrelvir), in healthy adults to potentially treat acute Covid-19 and long Covid.
Frontier Biotechnologies, a biopharmaceutical company focused on the discovery, development and dissemination of innovative medicines that improve...
VIENNA, Austria, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying Specific Active Immunotherapies (SAITs), today announced an exclusive collaboration and license agreement with Frontier Biotechnologies Inc. (688221.SH), a commercial-stage biopharmaceutical company, for the development and commercialization of AFFITOPE® AT04 for the treatment of patients with hypercholesterolemia in the Greater China region, including mainland China, Hong Kong, Macau and Taiwan. AFFITOPE® AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large phase 1 clinical study having recently been published. Shanghai-based Lynx Financial served as the sole financial advisor in this transaction.
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference.